News
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
Onco-Innovations successfully scales up key intermediates A83 and B4, advancing its CMC program for nanoparticle-based PNKP inhibitor drug ONC010. Collaborates with Dalton Pharma Services for process optimization and future GMP manufacturing -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
Onco-Innovations Limited announces advancement in analytical method for PNKP Inhibitor Technology, strengthening formulation development and scale-up for clinical manufacturing -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program
Onco-Innovations successfully completes milestone with Dalton Pharma Services, developing analytical method for purity determination of Intermediate 1 supporting ONC010, enhancing drug delivery system quality control -
-
